Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Inclusion Criteria

• Participant is able to provide signed informed consent
• Participant is female and ≥ 18 years of age or older if required by local laws or regulations
• Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis
• Participant has measurable and/or non-measurable disease
• Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)
• Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer
• Participant completed (neo) adjuvant taxane therapy at least 6 months prior to randomization
• Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization
• Participant completed all prior radiotherapy with curative intent ≥ 3 weeks prior to randomization
• Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting ≥ 2 weeks prior to randomization
• Participant's left ventricular ejection fraction is within normal institutional ranges
• Participant has resolution to grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to grade ≤ 2
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Participant is amenable to compliance with protocol schedules and testing
• Participant has adequate hematological functions [absolute neutrophil count (ANC) ≥ 1500 cells/microliter (mcL), hemoglobin ≥ 9 grams/deciliter (g/dL), and platelets ≥ 100,000 cells/mcL and ≤ 850,000 cells/mcL]
• Participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times the upper limit of normal (ULN), or ≤ 5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase ≤ 5.0 times the ULN]
• Participant has serum creatinine ≤ 1.5 x ULN. If serum creatinine > 1.5 x ULN the calculated creatinine clearance should be > 40 milliliters/minute (mL/min)
• Participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA); if urine protein ≥ 2+, a 24-hour urine collection must demonstrate 3 years
• Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80
• Participant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)
• Participant has a history of chronic diarrheal disease within 6 months prior to randomization
• Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization
• Participant has participated in clinical trials of experimental agents within 4 weeks prior to randomization
• Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
• Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within 14 days prior to randomization
• Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
• Participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric